Vendor Intelligence Report: Dragon Pharma

Executive summary

Dragon Pharma is an older-looking brand with a newer accountability problem. The manufacturer domain traces back to 2009 and archived pages show a mature pharmaceutical presentation by 2012, but the live buyer path has moved across retail domains. The current field capture validates dragonpharmastore.to as an official seller, after an earlier capture showed the same active storefront as unknown, making live channel verification central rather than cosmetic.

Across 1 Finnrick lab test the overall pass rate is 0%: 0 pass / 1 fail. The only Finnrick-tested product is Tesamorelin, and it failed under Finnrick’s methodology. The active ingredient identity was confirmed, so this is not framed as a wrong-compound finding; it is a product-specific quality warning. The record is too thin to judge the whole Dragon Pharma peptide catalog, but it also provides no reassurance for untested products.

The business record is similarly mixed. A UK company, Dragon Pharma Consultancy Ltd, gives the name a real corporate anchor, but its public filings do not disclose the actual retail operator, manufacturing site, import chain, or product-liability path. Paid releases shift from Dubai to London, while UAE registry checks did not corroborate a matching public registration. The active storefront shows current site maintenance, crypto-only checkout, and limited legal disclosure.

For buyers, Dragon Pharma is more defensible only through a currently manufacturer-verified channel and only with batch-level skepticism about vendor COAs. It is not a Finnrick-supported choice for Tesamorelin today. The full report separates brand continuity from retail-channel risk, including reseller exposure through Napsgear, copycat warnings, forum complaint history, and the limits of thin review-site sentiment.

Inside the full report:

• Dated channel timeline covering dragon-pharma.com, .com, .net, and .to storefront movement
• Companies House records for Dragon Pharma Consultancy Ltd and the named officer/PSC trail
• Dubai and London location-claim analysis with UAE registry dead-end documentation
• Verify Supplier captures showing the .to storefront moving from Unknown to Valid
• Storefront, payment-rail, reseller, and Napsgear distribution analysis
• Appendix A Finnrick Laboratory Data for the full Tesamorelin record and methodology views

Risk assessment

• Corporate ownership and accountability opacity — high: Dragon Pharma Consultancy Ltd, UK Company No. 10800038, is the only public anchor; the retail operator, ultimate owner, manufacturer, and Dubai/London location claims are not independently tied together.
• Crypto-payment and buyer-recourse risk — high: dragonpharmastore.to was observed using cryptocurrency-only checkout, leaving little chargeback leverage if a shipment is missing, counterfeit, seized, or harmful.
• Tesamorelin quality reliability risk — medium: Finnrick records show Dragon Pharma Tesamorelin has 1 total test, 0 pass / 1 fail, and a 44.35% rating; the sample count is thin but unfavorable for this product.
• Brand-confusion and channel-stability risk — medium: The store migrated from dragonpharmastore.net to dragonpharmastore.to, verification status changed across captures, and Dragon Pharma’s own scammers page documents copycats.
• Decentralized reseller traceability risk — medium: Napsgear and other third-party resellers carry/promote Dragon Pharma, which can obscure batch provenance and dispute accountability outside a verified direct channel.
• COA and batch-verification risk — medium: Vendor COAs reviewed are self-published/vendor-selected; the materials did not establish independent chain of custody or a batch-level link to the vial a buyer receives.